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Arterial Hypertension
Diagnosis and Treatment 
Jens Jordan, Christine Kurschat, Hannes Reuter
Summary
Background: Essential arterial hypertension is one of the main treatable cardiovascular risk factors. In Germany, approximately 
13% of women and 18% of men have uncontrolled high blood pressure (≥ 140/90 mmHg).
Methods: This review is based on pertinent publications retrieved by a selective literature search in PubMed. 
Results: Arterial hypertension is diagnosed when repeated measurements in a doctor’s office yield values of 140/90 mmHg or 
higher. The diagnosis should be confirmed by 24-hour ambulatory blood pressure monitoring or by home measurement. Further 
risk factors and end-organ damage should be considered as well. According to the current European guidelines, the target blood 
pressure for all patients, including those with diabetes mellitus or renal failure, is <140/90 mmHg. If the treatment is well toler-
ated, further lowering of blood pressure, with a defined lower limit, is recommended for most patients. The main non-pharmaco-
logical measures against high blood pressure are reduction of salt in the diet, avoidance of excessive alcohol consumption, smoking 
cessation, a balanced diet, physical exercise, and weight loss. The first-line drugs for arterial hypertension include long-acting dihy-
dropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, and thiazide-like 
diuretics. Mineralocorticoid-receptor blockers are effective in patients whose blood pressure cannot be brought into acceptable 
range with first-line drugs.
Conclusion: In most patients with essential hypertension, the blood pressure can be well controlled and the cardiovascular risk 
 reduced through a combination of lifestyle interventions and first-line antihypertensive drugs. 
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T he World Health Organization estimates that 54% of strokes and 47% of cases of ischemic heart disease are the direct consequence of high blood pressure, 
which thus takes its place among the main risk factors for 
cardiovascular morbidity and mortality (1). The declining 
incidence of stroke in recent decades is accounted for in 
large measure by the reduction of blood pressure (2). Even 
though the epidemiological association between high blood 
pressure and cardiovascular morbidity and mortality is well 
known, and despite the fact that sufficient evidence exists to 
justify antihypertensive treatment (3), blood pressure is 
often not adequately controlled. Either the blood pressure is 
not measured, or the phy sician fails to react in the face of 
elevated blood pressure values (4), or treatment is not pro-
vided optimally, or the patient fails to take the necessary 
medication regularly (5). In patients who suffer from treat-
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ment-resistant arte rial hypertension, the blood pressure can-
not be adequately controlled even if the patient does take 
the prescribed medication regularly. In patients with essen-
tial hypertension, none of the currently available clinical 
methods can detect a specific cause of the elevated blood 
pressure. Causes of secondary hypertension such as renal 
artery stenosis, hyperaldosteronism, or pheochromocyto-
ma, must be considered in the differential diagnosis, par-
ticularly in younger patients and those whose blood press-
ure is hard to control. Secondary types of hypertension 
call for specific diagnostic and therapeutic approaches 
(e.g., a pheochromocytoma must be resected) and will not 
be discussed here. In what follows, we provide an over-
view of the epidemiology and pathophysiology of essen-
tial arte rial hypertension and derive recommendations for 
the treatment of the affected patients. 
The direct consequences of high blood pressure
The World Health Organization estimates that 54% of strokes 
and 47% of cases of ischemic heart disease are the direct con-
sequence of high blood pressure, which is thus one of the 
main risk factors for cardiovascular morbidity and mortality.
Treatment-resistant arterial hypertension
In patients who suffer from treatment-resistant arterial hyper-
tension, the blood pressure cannot be adequately controlled 
even if the patient does take the prescribed medication regu-
larly.
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Learning objectives
This article should enable the reader to 
●  diagnose arterial hypertension and treat this lead-
ing cardiovascular risk factor, 
● be familiar with the definition of blood pressure 
target values for treatment, and 
●  know how to treat patients in conformity with the 
current guidelines. 
Methods
A selective search for original articles and reviews was 
carried out in PubMed with special attention to current 
guidelines and meta-analyses, which are given here as 
references. This article is also based on the authors’ 
scientific and clinical experience. 
Epidemiology
In the 1990s, the prevalence of arterial hypertension in 
Germany was still higher than the mean value among 
other Western countries. German epidemiological data 
from the years 2008–2011 reveal a decline in the fre-
quency of uncontrolled hypertension from 22% to 13% 
in women and from 24% to 18% in men (Figure 1) (6). 
Meanwhile, however, the prevalence among men aged 
18 to 29 rose from 4.1% to 8.5%. 
Pathophysiology
Elevated blood pressure must be due to elevated car-
diac output, elevated peripheral vascular resistance, or 
a combination of both. Each of these mechanisms is 
regulated, in turn, by hemodynamic, neural, humoral, 
and renal processes, all of which vary in their contribu-
tion from one individual to another (Figure 2). As per-
sons grow older, the predominant cause of hypertension 
tends to be elevated peripheral vascular resistance, 
often in combination with increased stiffness of the 
vessels, which manifests itself clinically as isolated 
systolic hypertension (7). Familial clustering implies 
a genetic predisposition whose interaction with envi-
ronmental factors, such as the intake of salt and calories 
and the degree of physical exercise, ultimately deter-
mines how severe the rise of blood pressure will be. 
Diagnostic evaluation and screening
In their current, updated joint guidelines on the diagnosis 
and treatment of arterial hypertension (8), the European 
Society of Cardiology (ESC) and the European Society of 
Hypertension (ESH) retain the threshold value of 
≥ 140/90 mm Hg for the definition of high blood pressure 
when measured in a doctor’s office. At least three 
measurements should be made on each of several days, 
with 1–2 minutes between measurements and with a 3–5 
minute pause before blood pressure is measured with the 
patient sitting. The optimal conditions for blood pressure 
measurement should be maintained (Box 1). Measure-
ments from the arm in patients with an arm circumference 
of 22–32 cm are made with a standard cuff (12–13 cm 
wide, 35 cm long); for larger upper arms, cuffs that are 
15–18 cm wide are available. When the blood pressure is 
first measured, it should be measured on both sides. If the 
difference in the values obtained on the two sides is 
>20 mmHg systolic or >10 mmHg dia stolic, the following 
potential causes must be ruled out, and, if the blood press-
ure is lower on the left side, the possibility of an aortic 
isthmus stenosis should be considered:
● Aortic arch syndrome due to atherosclerosis, or, 
rarely, vasculitis; 
Pathophysiology
Elevated blood pressure must be due to elevated cardiac out-
put, elevated peripheral vascular resistance, or a combination 
of both. Each of these mechanisms is regulated, in turn, by 
 hemodynamic, neural, humoral, and renal processes, all of 
which vary in their contribution from one individual to another.
Epidemiology
German epidemiological data from the years 2008–2011 reveal 
a decline in the frequency of uncontrolled hypertension from 
22% to 13% in women and from 24% to 18% in men.
FIGURE 1
The prevalence of arterial hypertension in five geographic regions of Germany. In the German 
Health Interview and Examination Survey for Adults (Studie zur Gesundheit Erwachsener in 
Deutschland, DEGS1), the prevalence of arterial hypertension—defined as either documented 
high blood pressure values or the taking of medication to treat known hypertension—was 
 determined in the male (♂) and female (♀) population in the period 2008–2011. The figure in 
parentheses is the percentage of hypertensive persons whose blood pressure was controlled 
with treatment [modified from [7])
♂ 29.7% (contr. 47.6%) 
♀ 31.4% (contr. 59.3%)
♂ 33.9% (contr. 44.3%) 
♀ 29.4% (contr. 58.7%)
♂ 31.3% (contr. 41.2%) 
♀ 25.9% (contr. 55.4%)
♂ 39.0% (contr. 45.9%) 
♀ 39.8% (contr. 53.5%)
♂ 36.6% (contr. 56.2%) 
♀ 30.5% (contr. 61.1%)
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● Unilateral subclavian artery stenosis;
● Aortic dissection.
Further measurements are subsequently always 
made on the arm with the higher values. Ortho-
static hypotension is defined as a fall in blood 
pressure by more than  20 mmHg systolic and/or 
more than 10 mmHg diastolic after the patient has 
been standing for three minutes (9). If orthostatic 
hypotension is suspected, particularly in an elderly 
or diabetic patient, two further measurements 
should be made 1 and 3 minutes later, with the pa-
tient still standing. 
The diagnosis should be confirmed by a 24-hour 
ambulatory  measurement or by automated home 
blood pressure measurements. The values obtained by 
these methods are usually lower than those obtained 
in the doctor’s office. This fact is taken into account 
by the lower recommended cutoff values (8). A 
24-hour ambulatory  measurement is also particularly 
helpful for ascertaining the presence of white-coat 
hypertension or of masked hypertension. 
A patient with white-coat hypertension regularly 
has an elevated blood pressure in the doctor’s office, 
but normal values when measured at home. The 
prevalence of this phenomenon in the general popu-
lation is approximately 13% (10). The long-term risk 
of cardiovascular events may be slightly higher in 
persons with white-coat hypertension than in persons 
without it (11).
In contrast, masked hypertension is the situation in 
which the measured blood pressure values are normal 
in the doctor’s office, but elevated at home. It is more 
common in young people, males, smokers, over-
weight or diabetic persons, and those suffering from 
anxiety or stress (12). The incidence of cardiovascular 
events in persons with masked hypertension is similar 
to that of persons with persistently elevated blood 
pressure (13).
10–15% of persons with hypertension have sec-
ondary hypertension due to a potentially treatable 
cause. If the history and basic diagnostic assessment 
suggest this possibility (Box 2), a targeted supplementary 
White-coat hypertension
A patient with white-coat hypertension regularly has an ele -
vated blood pressure in the doctor’s office, but normal values 
when measured at home. The prevalence of this phenomenon 
in the general population is approximately 13%.
Orthostatic hypotension
Orthostatic hypotension is defined as a fall in blood pressure 
by more than 20 mmHg systolic and/or more than 10 mmHg 
diastolic after the patient has been standing for three minutes 
(9).
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FIGURE 2 
The pathophysiology of essential arterial hypertension. Multiple hemodynamic, neural, humoral, and renal mechanisms lead to increased
cardiac output and/or peripheral vascular resistance. The product of these two hemodynamic variables determines the blood pressure.  
ANP, atrial natriuertic peptide; BNP, B-type natriuretic peptide; RAAS, renin-angiotensin-aldosterone system
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evaluation should be performed (Table 1). The patient 
should be asked about his or her intake of substances 
that elevate blood pressure, including licorice, 
 amphetamines, cocaine, oral contraceptive drugs, 
mineralo- and glucocorticoids, nonsteroidal anti-
 inflammatory drugs, erythropoietin, and cyclo -
sporine. Anticancer drugs, particularly angiogenesis 
 inhibitors and tyrosine kinase inhibitors, can also 
elevate blood pressure.
High blood pressure is usually accompanied by 
other cardiovascular risk factors that further potenti-
ate the risk. It follows that an evaluation of the pa-
tient’s overall risk should always be the first objective 
(Box 3).
According to the current recommendation, the 
higher the patient’s overall cardiovascular risk, the 
more strictly the blood pressure should be controlled 
and the earlier drug treatment should be initiated 
 (Figure 4) (8). Moreover, before any treatment is 
given, the potential causes of secondary hypertension 
should be excluded (Table 1). The possibility of pseu-
doresistance to treatment due to white-coat hyperten-
sion or suboptimal drug compliance should be borne 
in mind. Compliance can be checked by blood pres -
sure measurement after supervised drug intake, or 
else by measurement of the active substance(s) in the 
patient’s serum or urine. These factors are too often 
left out of consideration, even by specialists (14). In 
one study, out of 731 patients carrying the diagnosis 
of treatment-resistant hypertension, 26.5% actually 
had either pseudoresistant essential hypertension or a 
secondary type of hypertension. In 47% of cases, 
blood pressure became normal after a suitable change 
in the drug regimen (14).
Treatment
Target values for blood pressure
According to the update of the European ESH/ESC 
guidelines (2018), all patients, including those with 
renal failure or diabetes, should have their blood pres -
sure reduced to less than 140/90 mmHg (as measured 
in the doctor’s office) at the beginning of their treat-
ment (8). Most patients will tolerate this well; for those 
who do, a further reduction of blood pressure is recom-
mended. A target blood pressure range is defined, 
 including a lower limit (8). For patients aged 18–65, a 
target systolic blood pressure below 130 mmHg, but no 
less than 120 mmHg is suggested. The same holds for 
diabetic patients, whereas the recommendation for 
 patients with renal failure is a somewhat higher target 
systolic blood pressure range (below 140 mmHg, but 
no less than 130 mmHg). For patients over age 65, the 
Blood pressure target values
According to the update of the European ESH/ESC guidelines 
(2018), all patients, including those with renal failure or dia-
betes, should have their blood pressure reduced to less than 
140/90 mmHg (as measured in the doctor’s office) at the 
 beginning of their treatment.
Masked hypertension
Masked hypertension is the situation in which the measured 
blood pressure values are normal in the doctor’s office, but 
elevated at home. It is more common in young people, males, 
smokers, overweight or diabetic persons, and those suffering 
from anxiety or stress. 
BOX 1
Recommendations for blood pressure 
measurement in the doctor’s office and 
at home (e16)
● The bladder should be emptied before measurement.
● The patient should not consume coffee, alcohol, or 
 tobacco for at least one hour before the measurement.
● The patient should be seated for 3–5 minutes before the 
measurement in quiet surroundings at a pleasant 
 temperature. 
● Measurement in a relaxed, seated position, with backrest. 
● The patient’s arm should be free of clothing.
● The legs should be planted on the floor, not crossed.
● The arm should be relaxed and should rest on a firm 
 surface during the measurement. 
● Cuff size suitable for arm circumference. 
● The site of the measurement should be at heart level.
● At least 2 measurements should be taken 1–2 minutes 
apart. The patient should remain quietly seated without 
moving or talking. 
BOX 2
Signs suggesting secondary hypertension
● Evidence from the basic diagnostic work-up
● Severe and, especially, malignant hypertension
● Intractability
● Persistent blood pressure elevation after a long period 
of good blood pressure control 
● Hypertension of sudden onset
● Lack of a nocturnal drop in blood pressure (“non-
dipper”) or even a nocturnal rise in blood pressure (“re-
verse dipper”) in the 24-hour long-term measurement
● Unusual age of onset (before age 30 or after age 60)
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recommended target systolic blood pressure range is 
also below 140 mmHg, but no less than 130 mmHg. 
The target diastolic blood pressure range for all 
 patients, regardless of age, is below 80 mmHg, but no 
less than 70 mmHg. In elderly patients in particular, 
 attention must be paid to side effects, and the blood 
pressure target may have to be reset. The available 
scientific evidence on the treatment of high blood 
pressure in the elderly is limited, because the elderly 
are often  excluded from clinical trials (15). 
The German High Blood Pressure League recom-
mends the reduction of blood pressure to less than 
135/85 mmHg only in patients who have a high 
 cardiovascular risk (16), stating that the advantage of 
low systolic blood pressure has not yet been demon-
strated for hypertensive patients who suffer from dia-
betes mellitus, have already sustained a stroke, or are 
physically handicapped or dependent on nursing care.
The U.S. American cardiological societies, in the 
most recent update of their guidelines, classify blood 
pressure values in the range of 130–139/85–89 mmHg 
as grade I hypertension, but state that this should 
 initially be treated without drugs in most cases 
 (Figure 3) (17, 18). In the updated European guide-
lines, this is designated as the upper range of normal 
blood pres sure, and it is recommended that drug treat-
ment be considered for patients with blood pressure in 
this range only if their cardiovascular risk is very high 
(Figure 4) (8). More liberal cutoff values for high 
blood pressure are set by the United Kingdom’s 
National Institute for Health and Care Excellence 
(NICE) (19), which defines hypertension as an initial 
measurement ≥ 140/90 mm Hg with subsequent 
measurements ≥ 135/85 mm Hg (Figure 3).
The association of blood pressure with the occur-
rence of cardiovascular events in patients at high risk 
can be depicted by a J-shaped curve: over-aggressive 
blood pressure reduction (to <120 mmHg systolic or 
<70 mmHg diastolic) only causes more side effects 
without any further reduction of cardiovascular 
events (20). On the other hand, the findings of the 
Systolic Pressure Intervention Trial (SPRINT) con-
tributed to a downward trend in blood pressure cutoff 
values in the U.S. American and European guidelines. 
In this trial, 9361 patients over age 50 with a high car-
diovascular risk, but without diabetes mellitus, were 
randomized to systolic blood pressure reduction to 
either <120 mmHg or <140 mm Hg (21). Over a 
mean follow-up time of 3.26 years, the patients with 
the lower blood pressure target had a lower incidence 
of a combined cardiovascular endpoint (hazard ratio 
[HR]: 0.75, 95% confidence interval: [0.64; 0.89]) 
High-risk patients
The association of blood pressure with cardiovascular events 
in patients at high risk can be depicted by a J-shaped curve: 
over-aggressive blood pressure reduction (to <120 mmHg 
 systolic or <70 mmHg diastolic) only causes more side effects 
without any further reduction of cardiovascular events.
Blood pressure target values in the NICE guideline
NICE defines hypertension as an initial measurement of 
≥ 140/90 mmHg with subsequent measurements of 
≥ 135/85 mmHg.
TABLE 1
The causes, prevalence,* and diagnostic evaluation of secondary hypertension
CT, computed tomography; TSH, thyroid-stimulating hormone; fT3, free triiodothyronine; fT4, free tetraiodothyronine; MRI, magnetic resonance imaging;  
MIBG scintigraphy, metaiodobenzylguanidine scintigraphy. *Prevalence in a collective of patients with arterial hypertension (e17)
Cause
Hyperaldosteronism
Cushing syndrome
Pheochromocytoma
Thyroid diseases
Renal parenchymal 
diseases
Renal artery stenosis
Sleep apnea
Aortic isthmus stenosis
Prevalence*
1.4 –10%
0.5%
0.2 – 0.5%
1– 2%
1.6 – 8%
1– 8%
>5 –15%
<1%
Primary diagnostic evaluation
Laboratory testing
Aldosterone-renin quotient and absolute 
serum aldosterone concentration
Cortisol in 24-hour urine sample
Metanephrines in plasma
Measurement of serum TSH, fT3, and fT4 
Renal ultrasonography
 Urinalysis
Duplex ultrasonography of the kidneys
and renal arteries
Polygraphy
Blood pressure difference right vs. left arm 
and upper vs. lower limb
Echocardiography
Confirmatory test
• Sodium chloride tolerance test
• CT or MRI of the adrenal glands
• Selective adrenal venous sampling
Dexamethasone suppression test
•  CT or MRI of the abdomen
• 123I-MIBG scintigraphy
Thyroid ultrasonography or scintigraphy
Detailed work-up for renal disease
Contrast-enhanced CT or MRI of the renal 
arteries
Polysomnography
Contrast-enhanced CT or MRI of the 
 thoracic aorta
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and a lower risk of death from a cardiovascular cause 
(HR: 0.57 [0.38; 0.85]. The patients with the lower 
blood pressure target achieved a mean systolic blood 
pressure of 121 mmHg over a three-year period by 
taking a mean of 2.8 antihypertensive drugs, while 
those with the lower target achieved a mean systolic 
blood pressure of 134 mmHg by taking a mean of 1.8 
antihypertensive drugs. The automated blood-pres -
sure measurements in this trial were carried out after a 
five-minute rest period and without medical supervi-
sion, resulting in values that were a mean of 
12.7/12.0 mmHg lower than those obtained in a con-
ventional doctor’s office setting (22). It follows that 
these findings are not directly applicable to routine 
outpatient care. 
A somewhat different picture arose from a Coch-
rane Review concerning the question whether a reduc-
tion of blood pressure by 9.5/4.9 mmHg (down to 
≤ 135/85 mmHg from starting values of 
140–160/90–100 mmHg) might lower morbidity and 
mortality in patients already suffering from cardiovas-
cular disease (23). Data derived from 9795 subjects, 
including data from SPRINT, were evaluated; no dif-
ference was seen either in overall mortality (relative 
risk [RR] 1.05 [0.90; 1.22]) or in cardiovascular mor-
tality (RR 0.96 [0.77; 1.21]). Lower blood pressure 
did, however, lead to a 1.6% absolute risk reduction 
for fatal and non-fatal cardiovascular events. A further 
meta-analysis concerned the effects of reducing blood 
pressure from 150–160/95–105 mmHg to <140/90 
mmHg in elderly patients with a mean age of 75 years 
(24). A total of 8221 patients from three different trials 
were included in this meta-analysis, with SPRINT pa-
tients excluded for methodological reasons. There was 
no statistically significant effect on overall mortality, 
stroke, or serious cardiovascular events. Overall, it 
was concluded that there is an individual, relatively 
narrow blood pressure corridor that can be recom-
mended for each patient on the basis of his or her age, 
comorbidities, and ability to tolerate the treatment. It 
remains to be seen whether this concept can be practi-
cally applied in routine clinical situations. 
Non-pharmacological treatment
The two pillars of antihypertensive treatment are non-
pharmacological treatment and drug treatment (Figure 
4). Lifestyle changes are always to be considered first 
as a means of lowering blood pressure (8), and it makes 
sense to maintain these changes even after the later 
initiation of drug treatment. The most important 
measures are a low-salt diet, adequate potassium 
Non-pharmacological treatment
The most important measures are a low-salt diet, adequate 
potassium intake, avoidance of excessive alcohol con-
sumption, smoking cessation, a healthy, balanced diet, 
physical exercise, and weight loss. 
BOX 3
 Risk factors and signs of organ damage due to hypertension* 
● Risk factors
– Male sex
– Age (♂ ≥ 55 years; ♀ ≥ 65 years) 
– Smoking (now or in the past) 
– Dyslipidemia
   – Total cholesterol >190 mg/dL and/or
   – HDL-cholesterol ♂ <40 mg/dL; ♀ <46 mg/dL and/or
– Fasting blood glucose 102–125 mg/dL
– Hyperuricemia
– Obesity
   – Body mass index (BMI) ≥ 30 kg/m² and/or
   –  Abdominal obesity (waist circumference ♂ ≥ 102 cm; ♀ ≥ 88 cm) 
– Cardiovascular disease in a first-degree relative (♂ <55 years; ♀ <65 
years) 
– Family history of early onset of arterial hypertension
– Premature menopause 
– Sedentary lifestyle
– Psychosocial and socioeconomic factors 
– Heart rate >80/min at rest
●  Asymptomatic end-organ damage 
– Pulse pressure (in an elderly individual) ≥ 60 mm Hg 
– Carotid-femoral pulse wave velocity >10 m/s 
– Left-ventricular hypertrophy
– Electrocardiographic signs (Sokolow–Lyon index >3.5 mV, etc.) and/or
– Echocardiographic signs (left-ventricular mass index: ♂ >115 g/m²; 
♀ >95 g/m²) 
– Advanced retinopathy (hemorrhges or exudates, papilledema) 
– Ankle–arm index <0.9 
– Renal failure, moderate (eGFR >30–59 mL/min/1.73 m2) or severe 
(eGFR <30 mL/min/1.73 m2) 
– Microalbuminuria (30–300 mg/24 hr or 30–300 mg/g creatinine) 
●  Diabetes mellitus 
– Fasting blood glucose ≥ 126 mg/dL in at least two measurements and/or
– HbA1c >7% and/or
– Postprandial blood glucose >199 mg/dL
●  Overt cardiovascular or renal disease
– Cerebrovascular disease 
   – Ischemic stroke
   –  Subarachnoid hemorrhage
   –  Transient ischemic attack
● Coronary heart disease
   – Myocardial infarction
   – Angina pectoris
   – Myocardial revascularization, surgical or interventional
– Heart failure, systolic or diastolic
– Peripheral arterial occlusive disease 
– Demonstration of atheromatous plaque by imaging study 
– Atrial fibrillation
* modified from (8), eGFR, estimated glomerular filtration rate
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 intake, avoidance of excessive alcohol consumption, 
smoking cessation, a healthy, balanced diet, physical 
exercise, and weight loss. 
In a meta-analysis, the reduction of salt intake from 
201 mmol/day (a fairly typical value for the German 
population) to 66 mmol/day lowered blood pressure 
by a mean of 5.5/2.9 mmHg in white hypertensive pa-
tients (25). The effect is variable, however: not every 
patient benefits from a low-salt diet. Some antihyper-
tensive drugs, particularly inhibitors of the renin-
 angiotensin-aldosterone system, tend to be more 
 effective if the patient is on a low-salt diet (26). 
 According to the ESH/ESC guidelines, daily salt 
 intake should not exceed 5 g (8). Potassium intake can 
be  increased by increased consumption of vegetables 
and fruit. 
In randomized controlled trials, regular endurance 
training lowered blood pressure by a mean of 11/5 
mmHg (27, 28). The strongest effect was found in 
 patients who exercised during 40- to 60-minute peri-
ods at least three times per week. A meta-analysis re-
vealed that regular dynamic strength training can also 
positively affect blood pressure (29, 30).
Overweight and obese persons are at higher risk for 
arterial hypertension, need more antihypertensive 
medication, and are more commonly resistant to 
 treatment than patients with normal weight (31, 32). It 
is currently recommended that all persons should 
have a body-mass index between 20 and 25 kg/m2, 
with a waist circumference less than 94 cm in men 
and 80 cm in women (14). The value of weight-
 reducing drugs for obese hypertensive patients is un-
clear (33, 34). The massive weight reduction brought 
about by bariatric surgery is associated with an initial 
marked improvement in blood pressure (35). Over the 
long term, however, this effect seems to diminish, and 
persistent weight reduction by at least 10 kg is needed 
to lower systolic blood pressure by 6 mmHg [−10.66; 
−1.38 mmHg] (36).
Antihypertensive pharmacotherapy
Drug treatment can be initiated with a single drug or a 
combined preparation (13, 37). The ESC and ESH, in 
their updated joint guideline, recommend that most 
 patients should take two antihypertensive drugs at the 
start of pharmacotherapy, preferably combined in a 
single tablet (8). The recommended first line of treat-
ment consists of preparations that are constituted from 
the following four drug classes: angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin II receptor sub-
type 1 (AT1) blockers (sartans), long-acting calcium 
channel blockers of the dihydropyridine type, and 
 thiazide-like diuretics (Table 2). Even though beta-
 adrenoreceptor blockers are inferior to these substance 
classes with respect to cardiovascular protection (38), 
they are considered a suitable component of first-line 
treatment in some countries. Beta-blockers are used in 
patients who suffer from angina pectoris, have sustained 
Hypertension and overweight
Overweight and obese persons are at higher risk for arterial 
hypertension, need more antihypertensive medication, and are 
more commonly resistant to treatment than patients with 
 normal weight. The value of weight-reducing drugs for obese 
hypertensive patients is unclear.
Lifestyle changes
In randomized controlled trials, regular endurance training 
 lowered blood pressure by a mean of 11/5 mmHg. The 
 strongest effect was found in patients who exercised during 
40- to 60-minute periods at least three times per week.
FIGURE 3
Current classifications of high blood pressure
A comparison of the new definitions of normal blood pressure and the different grades of high blood pressure by the American Heart Association (AHA) and American College of Cardiology 
(ACC) with the definitions by the European Society of Cardiology (ESC) and European Society of Hypertension (ESH), as well as the most recent position of the German Hypertension League  
(Deutsche Hochdruckliga, DHL) and the National Institute for Health and  Care Excellence (NICE) of the United Kingdom. 
The lowering of cutoff values led to an increase in the prevalence of hypertension in the USA from 32% to 46%. 
*The value refers to further measurements in the outpatient setting or at home. 
 DBP, diastolic blood pressure; SBP, systolic blood pressure
SBP [mmHg]
<120
120–129
130–139
140–159
160–179
≥ 180
and 
and
or
or
or
or
DBP [mmHg]
<80
<80
80–89
90–99
100–109
≥ 110
ESH/ESC 2018
Optimal
Normal
Upper range of normal
Grade I hypertension
Grade II hypertension
Grade III hypertension
AHA/ACC 2017
Normal
Elevated
Grade I hypertension
Grade II hypertension
Grade II hypertension
Grade II hypertension
Position of the DHL, 2017
Optimal
Normal
Upper range of normal
Grade I hypertension
Grade II hypertension
Grade III hypertension
NICE 2016
Normal
Normal
Upper range of normal
Grade I hypertension 
(≥ 135/85 mmHg)*
Grade II hypertension  
(≥ 150/95 mmHg)*
Severe hypertension
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a myocardial infarction in the past, or have heart failure, 
or else for the control of heart rate (8). On the one hand, 
the choice of antihypertensive drug is based on individ-
ual efficacy and tolerability, for which there are still no 
good predictors; on the other hand, certain antihyperten-
sive drugs improve outcomes in patients with certain 
underlying diseases and should, therefore, be used 
 preferentially in these patients (Figure 5). Preparations 
with a long half-life that can be given once per day are 
preferable for reasons of compliance. In view of the cir-
cadian rhythms of circulatory regulation, it may be 
better for patients to take long-acting antihypertensive 
drugs in the evening (39), but it remains unclear whether 
this has any positive effect on cardiovascular events.
ACE inhibitors and AT1 receptor antagonists have 
been extensively studied in large-scale clinical trials 
(40). They improve the survival of patients with heart 
failure and have a beneficial effect on diabetic neph-
ropathy, and should therefore be given preferentially 
to patients with these conditions (Figure 5). They may 
also lower the risk of developing type 2 diabetes 
 mellitus (e1). Rising creatinine values and a corre-
sponding drop in the estimated glomerular filtration 
rate (eGFR) by as much as 30% after the initiation of 
treatment with an ACE inhibitor or an AT1 receptor 
antagonist are not infrequently seen, particularly in 
patients with diabetic nephropathy, and should not 
necessarily prompt the physician to discontinue these 
drugs. This phenomenon is due to the desired reduc-
tion of the blood pressure faced by the renal glomeru-
li, resulting in a functional reduction of the eGFR. 
AT1 receptor antagonists carry a much lower risk of 
inducing cough and angioedema, but their side-effect 
profile is similar to that of ACE inhibitors in other 
 respects (e2).
Calcium channel blockers of the dihydropyridine 
type are effective antihypertensive drugs and can, in 
principle, be combined with any other type of first-
line antihypertensive drug. Peripheral edema due to 
peripheral vasodilatation is a common side effect and 
sometimes leads to discontinuation of the drug (18). 
In a Cochrane analysis, the incidence of peripheral 
edema was 38% lower when the calcium channel 
blocker was given in combination with an ACE in-
hibitor or an AT1 receptor antagonist, probably 
 because of the relaxation of post-capillary resistance 
vessels brought about by the second drug (e3). 
 calcium channel blockers can cause or worsen 
ACE inhibitors and AT1 receptor antagonists
They improve the survival of patients with heart failure and 
have a beneficial effect on diabetic nephropathy, and should 
therefore be given preferentially to patients with these con -
ditions. They may also lower the risk of developing type 2 
 diabetes mellitus.
First-line treatment
First-line treatment consists of preparations that are constituted 
from the following four drug classes: angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin II receptor subtype 1 
(AT1) blockers (sartans), long-acting calcium channel blockers 
of the dihydropyridine type, and thiazide-like diuretics.
FIGURE 4
Recommendations for the initiation of antihypertensive drug therapy depending on the initial blood pressure measured in the doctor’s office 
(after [8]). BP, blood pressure; CAD, coronary artery disease; CVD, cardiovascular disease
Consider drug treatment 
for high-risk patients with 
CVD, particularly CAD 
Drug therapy for patients 
at low or moderate risk, 
without CVD,  renal 
 disease, or end-organ 
 damage after 3–6 months 
of a lifestyle intervention
Blood pressure control 
within 3 months should be 
the objective
Blood pressure control 
within 3 months should be 
the objective
High normal BP 
BP 130–139 / 85–89
Grade I hypertension 
BP 140–159/90–99
Grade II hypertension 
BP 160–179/100–109
Grade II hypertension 
BP ≥ 180/110
Lifestyle intervention Lifestyle intervention Lifestyle intervention Lifestyle intervention
Immediate drug therapy 
for high-risk and very-
high-risk patients 
Immediate drug therapy 
for all patients
Immediate drug therapy 
for all patients
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 constipation, particularly in elderly and immobile pa-
tients. They can also cause clinically significant drug 
interactions by inhibiting the enzyme cytochrome 
P450 3A4.
Thiazide-like diuretics have been a mainstay of 
antihypertensive treatment for decades (e4). Hydro-
chlorothiazide is the one most commonly prescribed 
around the world, even though it seems to be less 
 effective than indapamide or chlorthalidone (e5). 
Electrolyte disturbances are a common side effect, 
 especially in elderly patients (e6); the main types are 
hyponatremia and hypokalemia. 4.1% of elderly hy-
pertensive patients treated with chlorthalidone had a 
serum sodium concentration below 130 mmol/L (e7). 
The risk of hypokalemia is lower when a thiazide diu-
retic is given in combination with an ACE inhibitor, 
an AT1 receptor antagonist, or a potassium-sparing 
diuretic.
Beta-blockers are inferior to other first-line antihy-
pertensive drugs for the reduction of blood pressure 
(13, e8). They can cause weight gain (e9). Non-
 vasodilating beta-blockers have a deleterious effect 
on glucose metabolism (e10). Beta-blockers may 
worsen bronchoconstriction in patients with asthma. 
Nor should they be combined with verapamil or dil-
tiazem, two drugs that can slow the sinus rhythm or 
prolong atrioventricular conduction. Beta-blockers do 
improve the prognosis of patients who have sustained 
an acute myocardial infarction and/or suffer from 
chronic congestive heart failure, and they are, there-
fore, indicated for patients with these conditions, 
 independently of their antihypertensive effect (8). 
ACE inhibitors and AT1 receptor antagonists are con-
traindicated during pregnancy. Pregnant women may 
take older antihypertensive drugs such as dihydralazine 
and alpha-methyldopa; they may also take beta-blockers, 
such as metoprolol, and extended-release nifedipine. 
Dihydralazine and nifedipine, however, should not be 
given during the first trimester (e11).
Treatment-resistant hypertension
Even when all of these measures are taken, some 10% 
of hypertensive patients treated in routine clinical prac-
tice do not achieve adequate blood pressure control 
(e12, e13). The definition of treatment-resistant hyper-
tension is blood pressure that persistently remains over 
140/90 mmHg despite treatment with three antihyper-
tensive drugs in optimal doses, one of which is a 
 diuretic. The definition also requires the exclusion of 
potential causes of secondary hypertension. Treatment-
resistant hypertension often turns out to be treatable 
Pregnancy
ACE inhibitors and AT1 receptor antagonists are contra -
indicated during pregnancy. Pregnant women may take older 
antihypertensive drugs such as dihydralazine and alpha-
methyldopa; they may also take beta-blockers, such as 
 metoprolol, and extended-release nifedipine. 
Calcium channel blockers
Calcium channel blockers of the dihydropyridine type are 
 effective antihypertensive drugs and can, in principle, be 
 combined with any other type of first-line antihypertensive 
drug. Peripheral edema due to peripheral vasodilatation is a 
common side effect.
TABLE 2
Antihypertensive pharmacotherapy: dosages and common side effects*
*modified from (17, 19)
Drug class 
and examples
ACE inhibitors
Benazepril
Enalapril
Fosinopril
Lisinopril
Moexipril
Perindopril
Quinapril
Ramipril
Trandolapril
AT1-receptor antagonists
Azilsartan
Candesartan
Eprosartan
Irbesartan
Losartan
Olmesartan
Telmisartan
Valsartan
Thiazide-like diuretics
Chlorthalidone
Hydrochloro -
thiazide
Indapamide
Xipamide
Calcium antagonists of the dihydropyridine type
Amlodipine
Felodipine
Isradipine
Nifedipine (ex-
tended-release)
Nisoldipine
Recommended dosage
5–40 mg/day in one or two doses
5–20 mg/day in one or two doses
10–40 mg/day in one or two doses
5–40 mg/day once daily
7.5–30 mg/day in one or two doses
5–10 mg/day in one or two doses
10–40 mg/day in one or two doses
2.5–10 mg/day in one or two doses
1–4 mg/day in one or two doses
40–80 mg once daily
8–32 mg/day in one or two doses
600 mg/day in one or two doses
150–300 mg once daily
25–100 mg/day in one or two doses
10–40 mg once daily
20–80 mg once daily
80–320 mg once daily
12.5–25 mg/day
12.5–25 mg/day
2.5 mg/day
10–20 mg/day
2.5–10 mg once daily
2.5–10 mg once daily
2.5–10 mg once daily
40–80 mg/day in two doses
10–40 mg/day in two doses
Common side effects
Must not be combined 
with AT1-receptor 
 antagonists;  
Hyperkalemia,  
irritative cough, 
 elevated creatinine 
level in patients with 
chronic renal  failure or 
renal artery  stenosis,  
(rarely)  angioedema;
Contraindicated in 
pregnancy 
Must not be combined 
with ACE inhibitors;  
Hyperkalemia, 
 elevated creatinine 
level in patients with 
chronic renal failure or 
renal artery stenosis;
Contraindicated in 
pregnancy 
Hyponatremia (mainly 
in elderly female pa-
tients), hypokalemia,  
hypovolemia
Leg/ankle edema, 
constipation
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once the matter of patient compliance and the potential 
for further improvement of the drug regimen have been 
properly addressed; in our experience, the true preva-
lence of treatment-resistant hypertension is closer to 
4–5%. In these patients, the therapeutic spectrum must 
be widened in order to counteract the still unaltered, 
high cardiovascular risk. 
The treatment should be directed against two main 
pathophysiological mechanisms: overactivity of the 
sympathetic nervous system and volume excess due 
to excessive sodium retention, renal failure, or an ex-
cessively high aldosterone level. Hypervolemia can 
be countered with high-dose diuretics or with supple-
mentary treatment with a mineralocorticoid-receptor 
antagonist. This was confirmed in the Pathway 2 trial 
(e14): 285 hypertensive patients whose mean blood 
pressure, measured in the doctor’s office,  was 157/90 
mmHg under standard treatment with an ACE inhibitor 
or AT1 blocker, a calcium antagonist, and a diuretic at 
the highest tolerated doses were given either spironolac-
tone (25–50 mg), doxazosine (4–8 mg), bisoprolol 
(5–10 mg), or placebo for a period of 12 weeks in a 
double-blind crossover trial. If tolerated, the dose was 
doubled at 6 weeks. Absolute reduction of blood pressure 
was most pronounced with spironolactone (values of 
−12.8 mm Hg, −8.7 mm Hg, −8.3 mm Hg, and 
–4.1 mmHg, respectively). Blood pressure became 
 normal under this treatment in 58% of patients. The 
 frequency of serious side effects and the treatment dis-
continuation rate did not differ among treatment groups. 
Elevated activity of the sympathetic nervous system 
(e15) also provides the rationale for some of the interven-
tional techniques that have been developed for this group 
of patients. 
Conclusion
The treatment of arterial hypertension with a combi-
nation of lifestyle interventions and drugs can markedly 
lower cardiovascular risk. In most patients, blood press-
ure can be lowered effectively with first-line antihyper-
tensive drugs, but monotherapy often does not suffice. 
With regard to blood pressure target values, many ques-
tions remain open. We expect that the newly altered tar-
get values will give rise to a lively discussion of their ad-
vantages and potential risks in the very near future. 
Conclusion
In most patients, blood pressure can be lowered effectively 
with first-line antihypertensive drugs, but monotherapy often 
does not suffice.
 FIGURE 5
Recommendations for drug treatment of arterial hypertension with additional indications for 
first-line treatment because of further underlying diseases.  
ACE inhibitor,  angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker;  
EF, left ventricular ejection fraction. 
*1 in combination with a potassium-sparing diuretic, as indicated 
*2 symptomatic treatment for angina pectoris
Metabolic 
 syndrome
Renal failure / 
nephropathy
Coronary heart 
 disease
Systolic heart 
 failure
Atrial fibrillation
Left ventricular 
 hypertrophy
ACE inhibitor (or ARB), 
calcium antagonist
ACE inhibitor (or ARB)
ACE inhibitor (or ARB),  
beta-blocker
ACE inhibitor (or ARB), 
beta-blocker, diuretic
ACE inhibitor (or ARB), 
beta-blocker
ACE inhibitor (or ARB), 
calcium antagonist
Beta-blocker,  
diuretic*1
Calcium antagonist *2
Aldosterone antag-
onist (if EF ≤ 35 %)
Underlying disease First-line treatment Additional treatment
Aldosterone 
 antagonist
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Only one answer is possible per question. Please choose the most appropriate answer.
Question 1
How high is the prevalence of arterial hypertension in 
men aged 18 to 29?
a) 5.5%
b) 6.5%
c) 7.5%
d) 8.5%
e) 9.5%
Question 2
What pathophysiological cause of hypertension often 
 becomes most important with increasing age?
a) Elevation of peripheral vascular resistance 
b) Hyperinsulinemia
c) Renal failure
d) Elevation of cardiac output
e) Heart failure
Question 3
Your patient’s blood pressure measurements in your 
 office were always below 140/90 mmHg, but he obtained 
an elevated value on self-measurement with his wife’s 
sphygmomanometer. You ordered long-term measure-
ment over 24 hours and found a mean blood pressure of 
145/90 mm Hg.  What is the correct diagnosis? 
a) White-coat hypertension
b) Neurogenic hypertension
c) Normotension, because values in the doctor’s office were 
normal
d) Masked hypertension
e) Reverse dipper
Question 4
What underlying illness is the most common cause of 
secondary arterial hypertension? 
a) Cushing syndrome
b) Sleep apnea
c) Hyperaldosteronism 
d) Aortic isthmus stenosis
e) Renal artery stenosis
Question 5
What is the target blood pressure for all patients, includ-
ing those with renal failure and diabetes mellitus, as rec-
ommended in the updated European ESH/ESC guideline 
(2018)? 
a) <140/90 mmHg
b) <150/90 mmHg
c) <160/90 mmHg
d) <170/90 mmHg
e) <180/90 mmHg
Question 6
Which of the following persons, if hypertensive, has an elevated risk 
of organ damage?
a) 58-year-old male office clerk, smoker, 106 cm waist circumference
b) 64-year-old female farmer, heart rate 64/min at rest
c) 58-year-old female letter carrier, fasting blood glucose 85 mg/dL
d) 53-year-old male master carpenter, body-mass index 23 kg/m2
e) 53-year-old female physiotherapist, menopausal, total cholesterol 
165 mg/dL
Question 7
In what country did the prevalence of hypertension rise from 32% to 
46% when the threshold value was lowered? 
a) Belgium
b) France 
c) Germany 
d) The United Kingdom
e) The United States of America
Question 8
What lifestyle intervention lowered blood pressure by a mean of 
11/5 mmHg in randomized controlled trials?
a) Low-cholesterol diet
b) Weekly physical therapy
c) Regular endurance training
d) Increased calcium intake
e) Relaxation training by the Jacobsen technique
Question 9
Which of the following implies that hypertension is likely to be 
 secondary?
a) Night sweats
b) Lower blood pressure at night
c) Resistance to treatment
d) Tremor
e) Restless legs syndrome
Question 10
A 67-year-old woman (retired schoolteacher) with arterial hyperten-
sion and systolic heart failure is already taking an ACE inhibitor, a 
diuretic, and a beta-blocker as first-line treatment. Her left ventricular 
ejection fraction is less than 35%. What drug should you add on to 
her treatment?
a) An aldosterone antagonist
b) A calcium antagonist
c) An angiotensin receptor blocker
d) A benzodiazepine
e) A selective serotonin reuptake inhibitor
►Participation is possible only via the Internet: 
cme.aerzteblatt.de
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